Signal changes in T2-weighted MRI of liver metastases under bevacizumab-A practical imaging biomarker?
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
10
2019
accepted:
28
02
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
1
7
2020
Statut:
epublish
Résumé
The purpose of this study was to investigate signal changes in T2-weighted magnetic resonance imaging of liver metastases under treatment with and without bevacizumab-containing chemotherapy and to compare these signal changes to tumor contrast enhancement. Retrospective analysis of 44 patients, aged 36-84 years, who underwent liver magnetic resonance imaging including T2-weighted and dynamic contrast enhancement sequences. Patients received bevacizumab-containing (n = 22) or conventional cytotoxic chemotherapy (n = 22). Magnetic resonance imaging was obtained at baseline and at three follow-ups (on average 3, 6 and 9 months after initial treatment). Three independent readers rated the T2 signal intensity and the relative contrast enhancement of the metastases on a 5-point scale. T2 signal intensity of metastases treated with bevacizumab showed a significant (p<0.001) decrease in T2 signal intensity after initial treatment and exhibit compared to conventionally treated metastases significantly (p<0.001 for each follow-up) hypointense (bevacizumab: 0.70 ± 0.83 before vs. -1.55 ± 0.61, -1.91 ± 0.62, and -1.97 ± 0.52; cytotoxic: 0.73 ± 0.79 before vs. -0.69 ± 0.81, -0.71 ± 0.68, and -0.75 ± 0.65 after 3, 6, and 9 months, respectively). T2 signal intensity was strongly correlated with tumor contrast enhancement (r = 0.71; p<0.001). Intra-observer agreement for T2-signal intensity was substantial (κ = 0.75). The agreement for tumoral contrast enhancement between the readers was considerably lower (κ = 0.39). Liver metastases exhibit considerably hypointense in T2-weighted imaging after treatment with bevacizumab, in contrast to conventionally treated liver metastases. Therefore, T2-weighted imaging seems to reflect the effect of bevacizumab.
Identifiants
pubmed: 32231380
doi: 10.1371/journal.pone.0230553
pii: PONE-D-19-27984
pmc: PMC7108712
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0230553Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Magn Reson Imaging. 2015 Feb;33(2):201-12
pubmed: 25460330
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Cancer. 2007 Dec 15;110(12):2761-7
pubmed: 17960603
Neuro Oncol. 2012 May;14(5):667-73
pubmed: 22492961
Gastric Cancer. 2017 Jul;20(4):629-639
pubmed: 27995483
AJR Am J Roentgenol. 2016 Apr;206(4):756-63
pubmed: 26900904
Radiology. 1991 Aug;180(2):327-32
pubmed: 2068294
Cancer. 2014 Mar 1;120(5):711-21
pubmed: 24264883
Ann Oncol. 2017 Apr 1;28(4):754-760
pubmed: 27993816
Biometrics. 1977 Jun;33(2):363-74
pubmed: 884196
Magn Reson Imaging. 2015 Jul;33(6):725-36
pubmed: 25839393
Nat Rev Drug Discov. 2004 May;3(5):391-400
pubmed: 15136787
Clin Imaging. 2017 Jan - Feb;41:1-6
pubmed: 27721090
Radiology. 1986 Jul;160(1):49-52
pubmed: 3012632
Radiographics. 2013 Oct;33(6):1691-716
pubmed: 24108558
Int J Oncol. 2015 May;46(5):1883-92
pubmed: 25672376
World J Hepatol. 2017 Sep 18;9(26):1081-1091
pubmed: 28989564
J Clin Oncol. 2012 Dec 20;30(36):4566-72
pubmed: 23150701
J Nucl Med. 2013 Dec;54(12):2062-9
pubmed: 24136935
Eur Radiol. 2015 Jul;25(7):1993-2003
pubmed: 25636420
J Neurooncol. 2017 Jan;131(2):321-329
pubmed: 27896520
Radiology. 2016 Nov;281(2):484-498
pubmed: 27603788
JAMA. 2009 Dec 2;302(21):2338-44
pubmed: 19952320
EBioMedicine. 2017 Oct;24:34-42
pubmed: 29037604
Br J Cancer. 2011 Jun 28;105(1):139-45
pubmed: 21673686
Sci Rep. 2018 Mar 21;8(1):4990
pubmed: 29563601
AJR Am J Roentgenol. 2011 Dec;197(6):W1060-6
pubmed: 22109320
Neuro Oncol. 2014 Jun;16(6):868-79
pubmed: 24759636
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):123-132
pubmed: 26224536